ArticleScientific reports2026
Loss of Brg1 prevents the progression of pulmonary hypertension by inhibiting Nrf2 expression.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Brahma-related gene 1 (Brg1) is a major factor in regulation of chromatin remodeling and is involved in different cellular processes, including cell proliferation, apoptosis, and differentiation. However, the role of Brg1 in pulmonary artery hypertension (PAH) has not been elucidated. This study aims to assess the role of Brg1 in PAH using hypoxia-induced PAH rat model, Monocrotaline(MCT)-induced PAH rat model, and hypoxia-induced arterial smooth muscle cell model. We found that Brg1 expression was highly expressed in hypoxia-induced PAH rat model and MCT-induced PAH rat model. Moreover, knockdown of Brg1 by injection of adenoviral Brg1 shRNA inhibited Nrf2 expression and its downstream molecular HO-1, attenuated apoptosis resistance, and ameliorated PAH progression in PAH rats. Meanwhile, knockdown of Brg1 suppressed cell proliferation through downregulating the expression of mTOR/P70S6K signaling pathway in vitro and in vivo. In addition, the Nrf2 inhibitor Brusatol treatment significantly inhibited cell proliferation, whereas abrogated by loss of Brg1. In summary, these results demonstrated that loss of Brg1 inhibited PAH progression by downregulating Nrf2 to attenuate cell proliferation and enhance apoptosis, which may provide a new therapeutic target to improve cardiopulmonary function in PAH patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.